Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL.
Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL.
Urology. 2020 May;139:8-13. doi: 10.1016/j.urology.2020.01.029. Epub 2020 Feb 4.
To describe marijuana's clinical role for urologic symptoms.
Studies related to marijuana, voiding dysfunction, lower urinary tract symptoms (LUTS), and pain through January 2019 from PubMed were evaluated for relevance and quality.
Forty-eight studies were reviewed. Cannabinoids have mixed efficacy for neurogenic LUTS and little evidence for non-neurogenic LUTS, chronic non-cancer-related and perioperative pain. For cancer-related pain, high-level studies demonstrate cannabinoids are well-tolerated with unclear benefit.
Cannabinoids appear well-tolerated in the short-term, but their efficacy and long-term impact is unproven and unknown in urologic discomfort. Cannabinoids for urologic symptoms should be further explored with well-designed randomized controlled trials.
描述大麻在泌尿科症状方面的临床作用。
评估了 2019 年 1 月之前与大麻、排尿功能障碍、下尿路症状 (LUTS) 和疼痛相关的研究,以评估其相关性和质量。
共审查了 48 项研究。大麻素对神经原性 LUTS 的疗效不一,对非神经原性 LUTS、慢性非癌症相关和围手术期疼痛的证据很少。对于癌症相关疼痛,高水平的研究表明大麻素耐受性良好,但获益不明确。
大麻素在短期内似乎耐受性良好,但在泌尿科不适方面,其疗效和长期影响仍未得到证实,也不明确。大麻素在治疗泌尿科症状方面应进一步通过精心设计的随机对照试验进行探索。